SEC Comment Letter 0000000000-23-002818 to Tracon Pharmaceuticals, Inc. (TCON) (CIK 0001394319)
Tracon Pharmaceuticals, Inc. (TCON) (CIK 0001394319)
Date: March 21, 2023 · CIK: 0001394319 · Accession: 0000000000-23-002818
AI Filing Summary & Sentiment
File numbers found in text: 333-270589
Letter
United States securities and exchange commission logo March 21, 2023 Scott Brown Chief Financial Officer Tracon Pharmaceuticals, Inc. 4350 La Jolla Village Drive, Suite 800 San Diego, CA 92122 Re:Tracon Pharmaceuticals, Inc. Registration Statement on Form S-3 Filed March 16, 2023 File No. 333-270589 Dear Scott Brown: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Doris Stacey Gama at 202-551-3188 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Mattew T. Browne, Esq.
Show Raw Text
United States securities and exchange commission logo
March 21, 2023
Scott Brown
Chief Financial Officer
Tracon Pharmaceuticals, Inc.
4350 La Jolla Village Drive, Suite 800
San Diego, CA 92122
Re:Tracon Pharmaceuticals, Inc.
Registration Statement on Form S-3
Filed March 16, 2023
File No. 333-270589
Dear Scott Brown:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Doris Stacey Gama at 202-551-3188 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Mattew T. Browne, Esq.